Patent: 10,172,921
✉ Email this page to a colleague
Summary for Patent: 10,172,921
Title: | Method of treating an inflammatory bowel disease comprising agonists of orexin-1 receptor |
Abstract: | The present invention relates to methods and pharmaceutical compositions for the treatment of inflammatory bowel diseases. The presents methods relates to a method of treating an inflammatory bowel disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R agonist. |
Inventor(s): | Couvineau; Alain (Paris, FR), Voisin; Thierry (Paris, FR), Messal; Nassima (Paris, FR), Ogier-Denis; Eric (Paris, FR), Treton; Xavier (Paris, FR) |
Assignee: | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) UNIVERSITE PARIS DIDEROT--PARIS 7 (Paris, FR) ASSISTANCE PUBLIQUE--HOPITAUX DE PARIS (Paris, FR) |
Application Number: | 15/320,827 |
Patent Claims: | see list of patent claims |
Details for Patent 10,172,921
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2034-06-24 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 12/31/2002 | ⤷ Try a Trial | 2034-06-24 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 02/21/2008 | ⤷ Try a Trial | 2034-06-24 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 04/24/2013 | ⤷ Try a Trial | 2034-06-24 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |